Purpose: We evaluated the diagnostic accuracy of multiparametric magnetic resonance imaging and multiparametric magnetic resonance imaging/transrectal ultrasound fusion guided targeted biopsy against that of transperineal template saturation prostate biopsy to detect prostate cancer. Materials and Methods: We retrospectively analyzed the records of 415 men who consecutively presented for prostate biopsy between November 2014 and September 2016 at our tertiary care center. Multiparametric magnetic resonance imaging was performed using a 3 Tesla device without an endorectal coil, followed by transperineal template saturation prostate biopsy with the BiopSeeÒ fusion system. Additional fusion guided targeted biopsy was done in men with a suspicious lesion on multiparametric magnetic resonance imaging, defined as Likert score 3 to 5. Any Gleason pattern 4 or greater was defined as clinically significant prostate cancer. The detection rates of multiparametric magnetic resonance imaging and fusion guided targeted biopsy were compared with the detection rate of transperineal template saturation prostate biopsy using the McNemar test. Results: We obtained a median of 40 (range 30 to 55) and 3 (range 2 to 4) transperineal template saturation prostate biopsy and fusion guided targeted biopsy cores, respectively. Of the 124 patients (29.9%) without a suspicious lesion on multiparametric magnetic resonance imaging 32 (25.8%) were found to have clinically significant prostate cancer on transperineal template saturation prostate biopsy. Of the 291 patients (70.1%) with a Likert score of 3 to 5 clinically significant prostate cancer was detected in 129 (44.3%) by multiparametric magnetic resonance imaging fusion guided targeted biopsy, in 176 (60.5%) by transperineal template saturation prostate biopsy and in 187 (64.3%) by the combined approach. Overall 58 cases (19.9%) of clinically significant prostate cancer would have been missed if fusion guided targeted biopsy had been performed exclusively. The sensitivity of multiparametric magnetic resonance imaging and fusion guided targeted biopsy for clinically significant prostate cancer was 84.6% and 56.7% with a negative likelihood ratio of 0.35 and 0.46, respectively.
THE introduction of mpMRI has allowed for noninvasive localization of areas suspicious for PCa, in contrast to traditional random sampling of the organ by TRUS guided biopsy. 1 Further technological advances led to a combination of those methods by introducing mpMRI/ TRUS FTB platforms for targeted sampling of suspicious regions identified on imaging. 2, 3 To date the reference tests in studies evaluating the detection rate of FTB have been standard TRUS guided biopsy 3 or whole gland histology. 4 However, each of these methods have inherent disadvantages for histopathological correlation. Standard TRUS guided biopsy is inaccurate. 5, 6 Also, whole gland specimens introduce selection bias by only including patients diagnosed with PCa who qualify for radical treatment, thus, excluding men with false-negative biopsy results and low risk disease. 7, 8 It has been shown that FTB detects a higher proportion of csPCa with fewer cores than standard TRUS guided biopsies. 3 These results opened a debate on whether FTB alone without SB might be sufficient to detect csPCa. 9, 10 In our study we compared the performance of mpMRI and mpMRI/TRUS fusion guided targeted biopsy with TTSPB, a reference standard with better representation of the disease in the prostate gland than standard TRUS guided biopsy. 11 
PATIENTS AND METHODS

Study Design and Patient Selection
This retrospective analysis included all men who underwent mpMRI followed by TTSPB with the BiopSee fusion system between November 2014 and September 2016 at our academic tertiary care center. Patients previously treated for PCa were not included in study. Criteria described by the START (Standards of Reporting for MRI-Targeted Biopsy Studies) Consortium were followed when reporting this study. 12 The study was approved by the local ethics committee.
Imaging
All patients underwent mpMRI with triplanar T2-weighted, diffusion-weighted and dynamic contrast-enhanced sequences. In 68 patients (16%) mpMRI was performed elsewhere. In 347 patients (84%) MRI was performed without an endorectal coil on a whole body, 3 Tesla MAGNETOMÒ Skyra MRI system with 2 independent TimTX TrueShap transmit channels (Siemens, Iselin, New Jersey). The protocol and the sequence parameters were in accord with current international prostate MRI guidelines (supplementary table 1, http://jurology.com/). 13 All images where analyzed by board certified radiologists who were not blinded to clinical information. A 5-point Likert scale obtained from the clinical radiology reports was used to designate ROIs as 1dhighly unlikely, 2dunlikely, 3dequivocal, 4dlikely and 5dhighly likely to harbor clinically significant PCa. External mpMRIs without a Likert score were reviewed by the local radiologist. This Likert scale is a well established reporting scheme analogous to PI-RADSÔ (Prostate Imaging Reporting and Data System) which has been used in several studies. 7, 14, 15 
Biopsy Protocol
Transperineal biopsies were performed by 3 urologists with several years of experience with standard TRUS guided biopsy. Prostates were biopsied according to the 20 Barzell zones. For optimal organ coverage needles were placed using the BiopSee MRI/TRUS fusion biopsy system. In patients with suspicious ROIs, defined as a Likert score of 3 or greater on mpMRI, the lesions previously identified by the T2-weighted sequence were superimposed on the real-time TRUS images. Nonrigid fusion was performed using the BiopSee MRI/TRUS fusion biopsy system. 16 Two to 4 additional cores were obtained after completing systematic biopsies from each ROI.
Histopathology
Each single core that was taken was evaluated separately by a uropathologist. Tumor length was measured in each needle core and reported as the MCCL in mm. PCa was defined as clinically significant in the presence of any Gleason 4 pattern (GS 7 or greater). However, in the absence of a clear consensus on clinical significance 4 additional definitions were also applied to enable comparability with other studies. A n y c a n c e r ( P C a ) 
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A n y c a n c e r ( P C a ) MCCL thresholds of 4 mm or greater and 6 mm were based on TTSPB studies defining the MCCLs that provided more than 95% sensitivity to detect lesions 0.2 ml or greater and 0.5 ml or greater, respectively.
7,17
Data Analysis and Statistics
We compared the performance of TTSPB, FTB and the combination of TTSPB and FTB to detect PCa in patients with 1 or more ROIs and a Likert score of 3 or greater. The detection rate of csPCa is reported separately and for a combination of the 2 techniques. IBMÒ SPSSÒ, version 22.0 was used for descriptive statistics. The McNemar test was applied to compare the performance of different biopsy strategies. The unit of accuracy assessment was 1 patient (ie a whole prostate). Diagnostic accuracy measures of sensitivity, specificity, overall accuracy, positive predictive value, negative predictive value and LRs along with the 95% CIs were calculated with MedCalcÒ, version 17.2. Interval LRs were calculated as previously described 18 to demonstrate changes in pretest probability resulting from mpMRI and FTB results. Tests were 2-sided and considered statistically significant at p <0.05.
RESULTS
A total of 415 treatment na€ ıve patients underwent mpMRI followed by TTSPB during the study period. Table 1 lists clinical and radiographic characteristics. GS was 6 and 7 in 90 (54.2%) and 76 patients (45.8%), respectively, who had a prior biopsy positive for PCa. A median of 40 TTSPB cores (range 30 to 55) and 3 FTB cores (range 2 to 4) were taken. On mpMRI no or unsuspicious ROIs, defined as a Likert score of less than 3, were found in 124 men (29.9%). Of these patients TTSPB detected any PCa in 54 (43.5%) and csPCa in 32 (25.8%) ( fig. 1, a) . When considering only biopsy na€ ıve men, these rates were only slightly lower at 36.7% and 20.4%, respectively ( fig. 1, b) . Notably 4 patients (3.2%) had a GS 8 and 1 (0.8%) had GS 10 despite the absence of reported lesions on mpMRI.
In 291 patients (70.1%) at least 1 suspicious ROI (Likert score 3 or greater) was reported on mpMRI. TTSPB followed by FTB was successfully completed in all of these 291 patients. Figure 2 shows the PCa detection rates of combined biopsy, and FTB and TTSPB alone. The combined approach detected 222 PCa cases (76.3%), including 161 (55.3%) on FTB alone vs 220 (75.6%) on TTSPB alone (p <0.001). CsPCa was detected by the combined approach in 187 cases (64.3%), including 129 (44.3%) on FTB alone vs 176 (60.5%) on TTSPB alone (p <0.001).
Thus, adding FTB to TTSPB resulted in detection in an additional 11 patients (3.8%) while performing FTB alone without TTSPB would have missed 58 (19.9%) who harbored csPCa. Figure 3 shows detection rates based on prior biopsy status and Likert scores.
To address a possible confounding effect of the FTB learning curve we compared the detection rate of csPCa in the first 146 cases with that in the last 145. The incidence of cases missed by the FTB approach decreased from 21.9% to 18.0% (supplementary figure, http://jurology.com/).
We performed an additional subgroup analysis of the detection of low and high risk PCa. GS Figure 3 . Detection rates of PCa and clinically significant PCa (Gleason score 7 or greater) based on prior biopsy status and mpMRI Likert score. The mean AE SD MCCL in patients with a suspicious ROI was 5.3 AE 4.1 and 6.0 AE 4.2 mm for PCa and csPCa, respectively. These means were significantly higher than in patients without a suspicious ROI on mpMRI, including 3.1 mm for PCa and 3.4 mm for csPCa (p ¼ 0.02). Figure 4 shows the relationship between Likert scores and the presence of csPCa. TTSPB outperformed FTB for all Likert scores, including scores of 3, 4 and 5 (p ¼ 0.13, <0.001 and 0.001, respectively).
There was a direct association between lesion size on mpMRI and csPCa detection, including 29% for ROI less than 5 mm, 33% for ROI 5 to 9 mm and 50% for ROI 10 
DISCUSSION
Technological advances in mpMRI have led to the expectation that random biopsies of the prostate would no longer be necessary and could be replaced by targeted biopsies sometime in the near future, in accordance with the development of diagnostic pathways of other solid tumors. 1 In the current study we found that a significant number of men with negative mpMRI harbored clinically significant PCa. Furthermore, in the group with suspicious mpMRI 58 csPCa cases (19.9%) would have been missed without systematic biopsy (TTSPB). To our knowledge this is the first study evaluating the role of mpMRI and FTB based on highly extensive SB with a median number of 40 cores as the reference test.
Assessing the diagnostic error of mpMRI remains a major challenge. In previous investigations addressing mpMRI sensitivity and specificity for detecting PCa whole gland pathology (selection bias) 19e22 or standard TRUS guided biopsy (low accuracy) served as a reference standard. 23 This may explain the wide 44% to 87% range of reported sensitivity rates. 1 Recently for the first time Ahmed et al assessed the accuracy of mpMRI compared to TTSPB as the reference test. 7 Although scans were reported by dedicated urological radiologists with special training, mpMRI missed 12% of patients with GS 7 or greater disease. In the current study radiologists with different years of experience with reading prostate MRI reviewed the imaging, which might be a reason for the lower sensitivity. However, the Transperineal template saturation prostate biopsy was the reference test and since tumor detection on mpMRI is crucial step in fusion targeted biopsy diagnostic pathway, 32 men with false-negative mpMRI were included in fusion targeted biopsy accuracy analysis.
detection of csPCa in 20.4% of biopsy na€ ıve patients with negative mpMRI shows that MRI invisible cancer is common outside of prospective clinical trials. The false-negative rate remained significant at greater than 10% even when considering only tumors with a volume of 0.2 ml or greater and 0.5 ml or greater. The negative LR of unsuspicious mpMRI was 0.35 in the entire cohort, which is considered to indicate only a minor impact on the posttest probability. 24 Evaluating the accuracy of FTB for detecting PCa faces the same challenges as mpMRI in regard to the reference test. Groups have investigated the accuracy of FTB by comparing it to whole gland histology or standard TRUS guided biopsy. 3 Considering the known high false-negative rate of up to 50% for standard TRUS guided biopsy 7, 8 the frequently detected superiority of FTB is not surprising. 3 However, a clear trend toward lower FTB accuracy was observed when a superior SB was performed.
Siddiqui et al found FTB to be superior to standard TRUS guided biopsy with 16% more cases of csPCa (GS 7 or greater) detected. 9 In a similar study Filson et al also found FTB to be superior to SB but they detected only 13% more GS 7 or greater tumors by replacing standard TRUS guided biopsy with ArtemisÔ guided mapping biopsy. 25 Since FTB alone would have missed 60 cases of csPCa, the investigators concluded that the most accurate results were achieved by combining FTB and software guided SB.
Radtke 26 and Hansen 27 et al compared FTB to software guided TTSPB with a median of 24 cores. While the first study showed no advantage of any approach for detecting csPCa, the latter investigation revealed the superiority of TTSPB with an overall 9% higher detection rate (p <0.001). We could further confirm this trend. With a median of 40 cores our software guided TTSPB detected 19.9% more csPCa cases than FTB alone in an unselected and consecutive group of men being evaluated for PCa. With a negative LR of 0.6, FTB could not sufficiently lower the posttest probability to rule out PCa. 24 One could argue that this poorer performance was due to poor execution of the FTB technique. Recently reported detection rates of csPCa based on software based fusion were 16%, 33% and 69% in the study by Filson et al, 25 and 13%, 35% and 74% in the study by Mariotti et al 28 for scores of 3, 4 and 5, respectively, for lesions detected by mpMRI. With a slightly higher detection rate of 21%, 38% and 73%, respectively, the performance of FTB in the current study is comparable to that in the other reports, validating our FTB technique. Therefore, we do not attribute the better performance by TTSPB than by FTB to low accuracy of our FTB technique but rather to the significantly higher detection rate of software guided TTSPB compared to other SB techniques reported to date.
Yet FTB remains an error prone process. Radtke et al evaluated the diagnostic yield of mpMRI and FTB using whole gland histology. 19 They found that FTB performed less accurately to detect csPCa since it missed lesions that were accurately detected by mpMRI. A similar trend was observed in the current study with significantly higher sensitivity of mpMRI compared with FTB (csPCa detection 84.6% vs 56.7%).
It was believed that the inaccuracy of the FTB method 29 could be overcome by an in-bore MRI guided biopsy technique using a real-time image of the patient prostate. However, a systematic review did not show a higher detection rate for csPCa than for FTB despite the greater technical effort and higher costs. 30 Therefore, we believe that at the moment no targeted biopsy method can reliably and constantly place the needle in the ROI defined by imaging and achieve the higher accuracy of mpMRI in the detection of csPCa.
Limitations of this investigation are its retrospective nature and the heterogeneous population of men, including patients undergoing initial or repeat biopsy, patients on active surveillance or patients being evaluated for focal therapy. However, a subgroup analysis of biopsy na€ ıve patients revealed a similar detection rate. Furthermore, multiple radiologists not blinded to clinical data with different years of experience with reading prostate mpMRIs reported the examinations using a Likert score instead of the more common PI-RADS score. In contrast, either could also be considered a strength of the study since it more realistically reflects real-world clinical circumstances. Finally, we cannot rule out that cancers were missed by TTSPB and prostate swelling during fusion compromised the FTB detection rate.
CONCLUSIONS
Based on our analysis mpMRI alone should not be performed as a triage test in men being evaluated for suspected PCa due to a substantial number of false-negative csPCa results. SB using TTSPB outperformed software based FTB. Therefore, it will remain crucial in the diagnostic pathway of PCa until new modalities can provide reliable accuracy in daily clinical practice. 
EDITORIAL COMMENTS
In this clinically relevant study the authors assessed the diagnostic accuracy of mpMRI and FTB compared to TTSPB in a cohort of 415 consecutive patients. Beyond the study limitations which are clearly acknowledged by the authors, such as its retrospective nature and heterogenous population, the current study highlights the limitations of mpMRI with 25.8% of negative mpMRI cases harboring csPCa. Indeed, 19.9% of csPCa cases would have been missed if FTB alone has been performed, leading the authors to question the reliability of the FTB alone approach.
Of patients with suspicious mpMRI (Likert score 3 to 5) FTB detected csPCa in 44.3%, TTSPB detected csPCa in 60.5% and the combined approach detected csPCa in 64.3%. TTSPB outperformed FTB alone while the combined strategy appeared to be best, as supported by other contemporary studies (reference 27 in article). Combined FTB and TTSPB biopsies provided more complete and reliable sampling (reference 26 in article).
Currently mpMRI is limited in the detection of Gleason pattern 3 and possibly also in the detection of cribriform pattern 4.
1 This is of the utmost importance in the context of active surveillance and focal therapy strategies that cannot rely on sampling an index lesion, potentially missing contralateral, multifocal and even clinically significant disease.
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